Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Bock

Showing results (101-110 of 110) with videos related to

Pageof 11
Sort By:
You have reached the last page of results.This site can display upto 110 results.
The Lancet. HIV|November 4, 2022
Projected outcomes of universal testing and treatment in a generalised HIV epidemic in Zambia and South Africa (the HPTN 071 [PopART] trial): a modelling studyWilliam J M Probert, Rafael Sauter, Michael Pickles, et al.
Journal of the International AIDS Society|July 12, 2022
The association between HIV stigma and HIV incidence in the context of universal testing and treatment: analysis of data from the HPTN 071 (PopART) trial in Zambia and South AfricaJames R Hargreaves, Triantafyllos Pliakas, Graeme Hoddinott, et al.
Plos One|September 17, 2024
Identification of antibody targets associated with lower HIV viral load and viremic controlWendy Grant-McAuley, William R Morgenlander, Ingo Ruczinski, et al.
Journal of the International AIDS Society|October 31, 2025
Evaluation of pharmacokinetic interactions between long-acting cabotegravir or emtricitabine/tenofovir disoproxil fumarate and hormonal contraceptive agents: a tertiary analysis of South African participants in HPTN 084Mark A Marzinke, Brett Hanscom, Daniel Haines, et al.
Frontiers in Immunology|September 25, 2023
Comprehensive profiling of pre-infection antibodies identifies HIV targets associated with viremic control and viral loadWendy Grant-McAuley, William Morgenlander, Sarah E Hudelson, et al.
The Lancet. Global Health|March 15, 2021
Cost and cost-effectiveness of a universal HIV testing and treatment intervention in Zambia and South Africa: evidence and projections from the HPTN 071 (PopART) trialRanjeeta Thomas, William J M Probert, Rafael Sauter, et al.
Systematic Reviews|February 23, 2023
A systematic review of risk factors for mortality among tuberculosis patients in South AfricaTamaryn J Nicholson, Graeme Hoddinott, James A Seddon, et al.
Health Policy and Planning|May 8, 2021
Community-based health workers implementing universal access to HIV testing and treatment: lessons from South Africa and Zambia-HPTN 071 (PopART)Lario Viljoen, Tila Mainga, Rozanne Casper, et al.
The New England Journal of Medicine|July 18, 2019
Effect of Universal Testing and Treatment on HIV Incidence - HPTN 071 (PopART)Richard J Hayes, Deborah Donnell, Sian Floyd, et al.
Lancet (London, England)|April 4, 2022
Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trialSinead Delany-Moretlwe, James P Hughes, Peter Bock, et al.
Pageof 11

Showing results (101-110 of 110) with videos related to

Sort By:
Pageof 11
You have reached the last page of results.This site can display upto 110 results.
The Lancet. HIV|November 4, 2022
Projected outcomes of universal testing and treatment in a generalised HIV epidemic in Zambia and South Africa (the HPTN 071 [PopART] trial): a modelling studyWilliam J M Probert, Rafael Sauter, Michael Pickles, et al.
Journal of the International AIDS Society|July 12, 2022
The association between HIV stigma and HIV incidence in the context of universal testing and treatment: analysis of data from the HPTN 071 (PopART) trial in Zambia and South AfricaJames R Hargreaves, Triantafyllos Pliakas, Graeme Hoddinott, et al.
Plos One|September 17, 2024
Identification of antibody targets associated with lower HIV viral load and viremic controlWendy Grant-McAuley, William R Morgenlander, Ingo Ruczinski, et al.
Journal of the International AIDS Society|October 31, 2025
Evaluation of pharmacokinetic interactions between long-acting cabotegravir or emtricitabine/tenofovir disoproxil fumarate and hormonal contraceptive agents: a tertiary analysis of South African participants in HPTN 084Mark A Marzinke, Brett Hanscom, Daniel Haines, et al.
Frontiers in Immunology|September 25, 2023
Comprehensive profiling of pre-infection antibodies identifies HIV targets associated with viremic control and viral loadWendy Grant-McAuley, William Morgenlander, Sarah E Hudelson, et al.
The Lancet. Global Health|March 15, 2021
Cost and cost-effectiveness of a universal HIV testing and treatment intervention in Zambia and South Africa: evidence and projections from the HPTN 071 (PopART) trialRanjeeta Thomas, William J M Probert, Rafael Sauter, et al.
Systematic Reviews|February 23, 2023
A systematic review of risk factors for mortality among tuberculosis patients in South AfricaTamaryn J Nicholson, Graeme Hoddinott, James A Seddon, et al.
Health Policy and Planning|May 8, 2021
Community-based health workers implementing universal access to HIV testing and treatment: lessons from South Africa and Zambia-HPTN 071 (PopART)Lario Viljoen, Tila Mainga, Rozanne Casper, et al.
The New England Journal of Medicine|July 18, 2019
Effect of Universal Testing and Treatment on HIV Incidence - HPTN 071 (PopART)Richard J Hayes, Deborah Donnell, Sian Floyd, et al.
Lancet (London, England)|April 4, 2022
Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trialSinead Delany-Moretlwe, James P Hughes, Peter Bock, et al.
Pageof 11